AstraZeneca’s Tagrisso Combination Therapy Shows Improved Efficacy in EGFR-mutated NSCLC
UK-headquartered AstraZeneca (AZ; NASDAQ: AZN) has announced interim Phase III data demonstrating that the addition...
NASDAQ: AZN
AstraZeneca’s Ultomiris Faces FDA Rejection for NMOSD Indication Extension
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has received a rejection from the US Food...
Genentech Files for FDA Approval of Crovalimab for PNH, Challenging Soliris
Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has submitted its anti-C5 investigational drug, crovalimab,...
AstraZeneca’s Calquence Approved by NMPA for Chronic Lymphocytic Leukemia Treatment
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received another indication...
AstraZeneca’s Soliris Gains Approval for Pediatric Generalized Myasthenia Gravis in Japan
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced last week that it has received an...
AstraZeneca and Daiichi Sankyo’s Enhertu Earns Two BTDs for HER2+ Malignancies
The US Food and Drug Administration (FDA) has granted AstraZeneca (AZ; NASDAQ: AZN) and Daiichi...
HHS Releases List of 10 Drugs for Medicare Price Negotiations Starting 2026
The Department of Health and Human Services (HHS) in the US has released a list...
AstraZeneca Challenges US Government’s Drug Price Negotiation Plan for Medicare
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has filed a legal claim against the US...
AstraZeneca and MSD’s Lynparza Gets Green Light for Prostate Cancer Treatment in Japan
Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted AstraZeneca (AZ; NASDAQ: AZN) and...
AstraZeneca Restructures to Capture Opportunities in Guangdong-Hong Kong-Macao Greater Bay Area
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) is taking strategic steps to capitalize on the...
Scott-Moncrieff & Associates Preparing 50 Cases Against AstraZeneca Over Vaccine Concerns
Scott-Moncrieff & Associates, a UK-based law firm, has disclosed that it is preparing nearly 50...
AstraZeneca’s Forxiga Demonstrates Clinical Benefits in Heart Failure and COPD Patients
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced evidence that its SGLT2 inhibitor, Forxiga...
AstraZeneca’s Forxiga Gains New Indication Approval in China for Chronic Heart Failure
UK-based pharmaceutical major AstraZeneca plc (AZ, NASDAQ: AZN) has announced that China’s National Medical Products...
HutchMed’s Orpathys Receives Breakthrough Therapy Designation in China for Gastric Cancer
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its MET inhibitor, Orpathys (savolitinib),...
AstraZeneca to Invest Additional USD 250 Million in Qingdao for Aerosol Production Plant
UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) is set to invest an additional USD 250...
Burning Rock Partners with AstraZeneca to Develop Companion Diagnostics for Cancer Therapies
Guangzhou-based medical device giant Burning Rock (NASDAQ: BNR) has announced a strategic partnership with AstraZeneca...
CanSino Biotechnology Partners with AstraZeneca for mRNA Vaccine Development and Manufacturing
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced a product supply cooperation framework...
MSD’s Q2 2023 Earnings: Keytruda and Gardasil Drive Growth Amid COVID-19 Sales Decline
US-based major Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial results...
AstraZeneca’s Alexion Secures Gene Therapy Portfolio in Deal with Pfizer
AstraZeneca’s rare disease unit, Alexion (AZ, NASDAQ: AZN), has signed a significant purchase and license...
AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales
UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the...